IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v44y2021i9d10.1007_s40264-021-01087-7.html
   My bibliography  Save this article

Is There an Increased Risk of Hepatotoxicity with Metamizole? A Comparative Cohort Study in Incident Users

Author

Listed:
  • Karin Hedenmalm

    (European Medicines Agency
    Karolinska Institutet)

  • Alexandra Pacurariu

    (European Medicines Agency)

  • Jim Slattery

    (European Medicines Agency)

  • Xavier Kurz

    (European Medicines Agency)

  • Gianmario Candore

    (European Medicines Agency)

  • Rob Flynn

    (European Medicines Agency)

Abstract

Introduction The analgesic metamizole, which has been withdrawn from the market in several countries due to the risk of agranulocytosis but is still available on the market in Germany and some other countries, has been associated with liver injury in published case reports; however, epidemiological studies on the risk of liver injury are limited. Objective The aim of this study was to compare the risk of liver injury up to 270 days after the first start of treatment with metamizole with the corresponding risk in patients starting treatment with paracetamol, using a retrospective cohort incident user design. Methods The first prescription for either metamizole or paracetamol in the Intercontinental Medical Statistics (IMS)® Disease Analyzer Germany database during the study period (2009–2018) was identified in patients with at least 365 days of observation and no prior diagnosis of liver events, cancer or HIV, or treatment within the last 6 months with hepatotoxic drugs typically administered for chronic conditions. Each patient was followed for specific liver events for 90 days after the prescription. In case of a new prescription within 90 days, a new 90-day observation period started, up to a maximum of 270 days. Cox regression was used to compare the risk of liver injury in the two groups. Results Metamizole was associated with a higher risk of liver injury compared with paracetamol (adjusted hazard ratio 1.69, 95% confidence interval 1.46–1.97). Sensitivity analyses were performed to evaluate the robustness of these findings. In all the sensitivity analyses, metamizole was still associated with a higher risk of liver injury, including an analysis where naproxen was used as a comparator instead of paracetamol. Conclusions Results from this study support previous studies suggesting that metamizole is associated with a significant risk of liver injury. Nevertheless, a possible impact of residual confounding cannot be excluded.

Suggested Citation

  • Karin Hedenmalm & Alexandra Pacurariu & Jim Slattery & Xavier Kurz & Gianmario Candore & Rob Flynn, 2021. "Is There an Increased Risk of Hepatotoxicity with Metamizole? A Comparative Cohort Study in Incident Users," Drug Safety, Springer, vol. 44(9), pages 973-985, September.
  • Handle: RePEc:spr:drugsa:v:44:y:2021:i:9:d:10.1007_s40264-021-01087-7
    DOI: 10.1007/s40264-021-01087-7
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-021-01087-7
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s40264-021-01087-7?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:44:y:2021:i:9:d:10.1007_s40264-021-01087-7. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.